NCT00618345已完成2 期
Phase II Trial of RAD001 in Relapsed/Refractory Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 35
- 主要终点
- Confirmed response (complete response, very good partial response, partial response, or minimal response) of serum and urine monoclonal protein
研究概览
简要总结
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma.
详细描述
OBJECTIVES:
Primary
- To assess the response rate in patients with relapsed or refractory multiple myeloma treated with everolimus.
Secondary
- To evaluate the toxicity of everolimus in patients with multiple myeloma.
- To study the tumor cells and blood from patients entering this trial for laboratory correlates.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Confirmed response (complete response, very good partial response, partial response, or minimal response) of serum and urine monoclonal protein
次要结局
- Toxicity
研究者
相似试验
已完成
2 期
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentLeukemiaLymphoproliferative DisorderLymphomaNCT00436618Mayo Clinic277
终止
2 期
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous TherapyColorectal CancerNCT00390364Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
已完成
1 期
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT01062399Radiation Therapy Oncology Group279
终止
2 期
RAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesMyelodysplastic SyndromesNCT00809185Case Comprehensive Cancer Center7
已完成
2 期
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach CancerGastric CancerEsophageal CancerNCT00985192Translational Oncology Research International49